Article Sidebar

PDF
Issue: No. 101 (2026)
Section: Article
DOI: 10.58490/ctjump.2026i101.4732
Date Published: 20/08/2026
Views 0
Downloads 0
How to Cite
La, N. T., Le, T. B., To, Y. L., Nguyen, M. H., Ngo, T. H. T., & Nguyen, K. H. (2026). STUDY ON CLINICAL AND PARACLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF OVERACTIVE BLADDER WITH MIRABEGRON AT CAN THO UNIVERSITY OF MEDICINE AND PHARMACY HOSPITAL IN 2025 – 2026. Cantho Journal of Medicine and Pharmacy, 101, 333-339. https://doi.org/10.58490/ctjump.2026i101.4732

STUDY ON CLINICAL AND PARACLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF OVERACTIVE BLADDER WITH MIRABEGRON AT CAN THO UNIVERSITY OF MEDICINE AND PHARMACY HOSPITAL IN 2025 – 2026

Ngoc Tram La1, , Thanh Binh Le1, Yen Linh To1, Minh Hieu Nguyen1, Thi Huyen Trang Ngo1, Kim Ha Nguyen1
1 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: Overactive Bladder (OAB) is a common urological syndrome that, although not directly life-threatening, significantly impacts the quality of life. Mirabegron is one of the currently recommended medical treatments. Objectives: 1. To investigate the clinical and subclinical characteristics of patients diagnosed with overactive bladder at Can Tho University of Medicine and Pharmacy Hospital from 2025 to 2026. 2. To evaluate the treatment outcomes of Mirabegron for overactive bladder at Can Tho University of Medicine and Pharmacy Hospital from 2025 to 2026. Materials and methods:  A prospective cohort study was conducted on 31 patients diagnosed with OAB, indicated for Mirabegron treatment (dose of 50mg/day), and re-evaluated after 4 weeks of treatment at Can Tho University of Medicine and Pharmacy Hospital from June 2025 to June 2026. Results: The distribution was concentrated in the young and middle-aged groups, with a female predominance over males. The most common symptoms were urinary urgency (80.6%) and urinary frequency (74.2%). The majority of patients had mild severity (OAB-SS: 1-5 points: 87.1%) and a low impact on quality of life (QoL: 1-2 points: 77.4%). After treatment with Mirabegron, significant improvement was achieved, with the average decrease in OAB-SS and QoL scores being 1.84±1.42 points and 0.68±0.70, respectively. Conclusion: Overactive bladder in the study group was generally of mild severity, manifesting primarily as urinary urgency and frequency. Mirabegron is a highly effective treatment in reducing symptoms and significantly improving the patients' quality of life. 

Keywords

Overactive bladder, Mirabegron, OAB-SS, QoL

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

References

1. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002. 21(2), 167-178, https://doi.org/10.1002/nau.10052.
2. Vũ Lê Chuyên, Huỳnh Đoàn Phương Mai. Xác định tỷ lệ mắc bệnh bàng quang tăng hoạt của người lớn tại Việt Nam. Tạp chí Y Học Thành phố Hồ Chí Minh. 2016.20(2), 158-162.
3. Hội Tiết niệu - Thận học Việt Nam. Hướng dẫn chẩn đoán và điều trị bàng quang tăng hoạt. 2024. https://vuna.com.vn/c93/t93-78/vuna--huong-dan-chan-doan-va-dieu-tri-bang-quangtang-hoat.html.
4. Lightner D.J., Gomelsky A., Souter L., and Vasavada S.P. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019.202(3), 558-563, https://doi.org/10.1097/JU.0000000000000309.
5. Start K., Bell R., Bibby J., et al. Overactive Bladder Syndrome (OAB): Guidelines for prescribing. NHS Guideline. 2008.
6. Dawood O., and El-Zawahry A. Mirabegron. StatPearls Publishing. 2023. https://www.ncbi.nlm.nih.gov/books/NBK538513/.
7. Irwin D.E., Milsom I., Hunskaar S., Reilly K., Kopp Z., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006. 50(6), 1306-1314, https://doi.org/10.1016/j.eururo.2006.09.019.
8. Sexton C.C., Coyne K.S., Vats V., Kopp Z.S., Irwin D.E., et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. The American Journal of Managed Care. 2011. 17(2), e42-e51.
9. Cho S.Y., et al. Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study. Investig Clin Urol. 2020. 61(4), 419-424, doi: 10.4111/icu.2020.61.4.419.
10. Gotoh M., Homma Y., Funahashi Y., Matsukawa Y., and Kondo T. Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology. 2011. 78(4), 768773, https://doi.org/10.1016/j.urology.2011.06.015.